利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.009 秒)

    Use of 3-oxygermylpropionic acid to treat and prevent diabetes due to autoimmune diseases
    4.
    发明公开
    Use of 3-oxygermylpropionic acid to treat and prevent diabetes due to autoimmune diseases 失效
    使用引起的自身免疫性疾病糖尿病的治疗和预防的3-氧锗酸。

    公开(公告)号：EP0444931A2

    公开(公告)日：1991-09-04

    申请号：EP91301646.5

    申请日：1991-02-28

    申请人： SANWA KAGAKU KENKYUSHO CO., LTD.

    发明人： Sawai, Kiichi, c/o Sanwa Kagaku Kenkyusho Co., Ltd ,  Kurono, Masayasu, c/o Sanwa Kagaku ,  Mitani, Takahiko, c/o Sanwa Kagaku

    IPC分类号： A61K31/28 ,  A61K31/80

    CPC分类号： A61K31/28 ,  A61K31/80

    摘要： 3-hxygermylpropionic acid [O 1/2 )₃GeCH₂CH₂CO₂H] n ("3-0GP") has been known as a pharmaceutical agent, e.g for treating hepatopathy, preferably with a stabilizer and/or enhancer and can have immunity - accomodative actions.
    It is now found that 3-OGP is effective against a diabetes-dependent auto-immune disease and is used for manufacture of a medicament for its treatment or prevention.
    An activating carrier, e.g. hydroxypropyl cellulose, is preferably used in the composition, which may be in the form of tablets or capsules, in amount of 0.005 to 50 wt % of the 3-OGP. The preferable dose of the composition is 10 - 1500 mg/kg, or a daily adult dose of about 150 mg.

    摘要翻译： 3- hxygermylpropionic甲酸[O1 / 2）3GeCH2CH2CO2H] n的（“3-0GP”）已被公知作为药剂，e.g用于治疗肝病，优选用稳定剂和/或增强子，并且可具有免疫 - 调节性行动。 现在发现做了3 OGP是针对糖尿病相关的自身免疫疾病的有效，并用于制造用于其治疗或预防的药物。 在活化载体，E.G. 羟丙基纤维素，优选在组合物中，其可以是片剂或胶囊剂的形式，在0.005量提供给3-OGP的50％（重量）使用。 该组合物的优选剂量是从10至1500毫克/千克，或约150毫克成人每日剂量。

    Agent for treating diabetic keratopathy
    6.
    发明公开
    Agent for treating diabetic keratopathy 失效
    Mittel zur Behandlung von Keratopathie

    公开(公告)号：EP0719556A2

    公开(公告)日：1996-07-03

    申请号：EP95120021.1

    申请日：1995-12-19

    申请人： SANWA KAGAKU KENKYUSHO CO., LTD.

    发明人： Sawai, Kiichi, c/o Sanwa Kagaku Kenkyusho Co., Ltd ,  Ban, Masatoshi, c/o Sanwa Kagaku Kenkyusho Co, Ltd ,  Sato,Makoto, c/o Sanwa Kagaku Kenkyusho Co, Ltd ,  Hibi, Chihiro, c/o Sanwa Kagaku Kenkyusho Co, Ltd ,  Mizuno, Kuniharu, c/o Sanwa Kagaku Kenkyusho Co.

    IPC分类号： A61K31/415

    CPC分类号： A61K31/4188

    摘要： An agent for treating diabetic keratopathy which comprises (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamide as an active ingredient. It is in the form of, in particular, oral preparations or eye drops and composed of a composition which is efficacious against diabetic corneal epitheliopathy, diabetic corneal imperception and diabetic corneal endotheliopathy. The mechanism of diabetic keratopathy occurrence has not been clarified and thus no effective remedy therefor has been developed so far. It is a disease accompanied by various abnormalities in the corneal epithelium, perception (Schwann cells) and endothelial cells. When the cornea undergoes severe disintegration, vesicular keratopathy occurs and seriously damages the visual function. Thus it frequently becomes intractable. The present invention provides an efficacious treating agent for this disease.

    摘要翻译： 一种治疗糖尿病性角膜病的药剂，其特征在于，含有（2S，4S）-6-氟-2'，5'-二氧代环苯并噻喃-4,4'-咪唑啉-2-甲酰胺作为活性成分。 其特别是口服制剂或滴眼剂的形式，并且由对糖尿病性角膜上皮病，糖尿病角膜缺陷和糖尿病性角膜内皮细胞病变有效的组合物组成。 糖尿病性角膜病的发生机制尚未得到澄清，迄今尚未形成有效的治疗方法。 它是伴随着角膜上皮，感知（雪旺氏细胞）和内皮细胞的各种异常的疾病。 当角膜发生严重的分解时，发生囊泡性角膜病，严重损害视力。 因此，它经常变得棘手。 本发明提供了用于该疾病的有效治疗剂。